U.S., March 21 -- ClinicalTrials.gov registry received information related to the study (NCT06885957) titled 'Monoclonal Antibody-Based Therapies for AQP4-Positive NMOSD' on March 13.
Brief Summary: The primary objective of this registry study is to evaluate the therapeutic efficacy and safety profiles of distinct monoclonal antibody-based therapies for aquaporin-4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorders within the Chinese population under real-world clinical conditions. Secondary objectives include quantitative assessment of longitudinal neuroimaging biomarker variations and immunological profile alterations in longitudinal biological specimens pre- and post-therapeutic intervention.
Study Start Date: April ...